Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ALSUntangled #70: caffeine.
Hatch J, Barkhaus P, Barnes B, Beauchamp M, Benatar M, Bertorini T, Bowser R, Bromberg M, Brown A, Mascias Cadavid J, Carter GT, Cole N, Crayle J, Dimachkie M, Ennist D, Feldman E, Fullam T, Heiman-Patterson T, Jhooty S, Levine T, Li X, Lund I, Mallon E, Maragakis N, McDermott C, Pattee G, Pierce K, Ratner D, Staats K, Wicks P, Wiedau M, Bedlack R. Hatch J, et al. Among authors: ennist d. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Jun 8:1-5. doi: 10.1080/21678421.2023.2220742. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37288776
Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis.
Jahandideh S, Taylor AA, Beaulieu D, Keymer M, Meng L, Bian A, Atassi N, Andrews J, Ennist DL. Jahandideh S, et al. Among authors: ennist dl. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):294-302. doi: 10.1080/21678421.2017.1418003. Epub 2017 Dec 20. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29260584
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool.
Brooks BR, Pioro EP, Beaulieu D, Taylor AA, Schactman M, Keymer M, Agnese W, Perdrizet J, Apple S, Ennist DL. Brooks BR, et al. Among authors: ennist dl. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Feb;23(1-2):49-57. doi: 10.1080/21678421.2021.1927102. Epub 2021 Jul 10. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 34251911
Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic.
Beaulieu D, Berry JD, Paganoni S, Glass JD, Fournier C, Cuerdo J, Schactman M, Ennist DL. Beaulieu D, et al. Among authors: ennist dl. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(sup1):22-32. doi: 10.1080/21678421.2021.1924207. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 34348539
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Salomon-Zimri S, Pushett A, Russek-Blum N, Van Eijk RPA, Birman N, Abramovich B, Eitan E, Elgrart K, Beaulieu D, Ennist DL, Berry JD, Paganoni S, Shefner JM, Drory VE. Salomon-Zimri S, et al. Among authors: ennist dl. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):263-271. doi: 10.1080/21678421.2022.2119868. Epub 2022 Sep 15. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36106817 Clinical Trial.
ALSUntangled # 69: astaxanthin.
Fullam T, Armon C, Barkhaus P, Barnes B, Beauchamp M, Benatar M, Bertorini T, Bowser R, Bromberg M, Mascias Cadavid J, Carter GT, Dimachkie M, Ennist D, Feldman EL, Heiman-Patterson T, Jhooty S, Lund I, Mcdermott C, Pattee G, Ratner D, Wicks P, Bedlack R. Fullam T, et al. Among authors: ennist d. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):553-557. doi: 10.1080/21678421.2023.2171302. Epub 2023 Jan 24. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36694292 Review.
ALSUntangled #71: Nuedexta.
Sun Y, Benatar M, Mascías Cadavid J, Ennist D, Wicks P, Staats K, Beauchamp M, Jhooty S, Pattee G, Brown A, Bertorini T, Barkhaus P, Bromberg M, Carter G, Bedlack R, Li X. Sun Y, et al. Among authors: ennist d. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb;25(1-2):218-222. doi: 10.1080/21678421.2023.2239292. Epub 2023 Jul 26. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 37493197 Review.
Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis.
Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, Cudkowicz M, Paganoni S. Nicholson K, et al. Among authors: ennist dl. Ann Clin Transl Neurol. 2018 Oct 22;5(12):1522-1533. doi: 10.1002/acn3.671. eCollection 2018 Dec. Ann Clin Transl Neurol. 2018. PMID: 30564619 Free PMC article.
Predicting disease progression in amyotrophic lateral sclerosis.
Taylor AA, Fournier C, Polak M, Wang L, Zach N, Keymer M, Glass JD, Ennist DL; Pooled Resource Open‐Access ALS Clinical Trials Consortium. Taylor AA, et al. Among authors: ennist dl. Ann Clin Transl Neurol. 2016 Sep 7;3(11):866-875. doi: 10.1002/acn3.348. eCollection 2016 Nov. Ann Clin Transl Neurol. 2016. PMID: 27844032 Free PMC article.
Design and analysis of a clinical trial using previous trials as historical control.
Schoenfeld DA, Finkelstein DM, Macklin E, Zach N, Ennist DL, Taylor AA, Atassi N; Pooled Resource Open-Access ALS Clinical Trials Consortium. Schoenfeld DA, et al. Among authors: ennist dl. Clin Trials. 2019 Oct;16(5):531-538. doi: 10.1177/1740774519858914. Epub 2019 Jul 1. Clin Trials. 2019. PMID: 31256630 Free PMC article.
36 results